<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33661518</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2299-5684</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Pharmacological reports : PR</Title><ISOAbbreviation>Pharmacol Rep</ISOAbbreviation></Journal><ArticleTitle>Chemical chaperones targeted to the endoplasmic reticulum (ER) and lysosome prevented neurodegeneration in a C9orf72 repeat expansion drosophila amyotrophic lateral sclerosis (ALS) model.</ArticleTitle><Pagination><StartPage>536</StartPage><EndPage>550</EndPage><MedlinePgn>536-550</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s43440-021-00226-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">ALS is an incurable neuromuscular degenerative disorder. A familiar form of the disease (fALS) is related to point mutations. The most common one is an expansion of a noncoding GGGGCC hexanucleotide repeat of the C9orf72 gene on chromosome 9p21. An abnormal translation of the C9orf72 gene generates dipeptide repeat proteins that aggregate in the brain. One of the classical approaches for developing treatment against protein aggregation-related diseases is to use chemical chaperones (CSs). In this work, we describe the development of novel 4-phenylbutyric acid (4-PBA) lysosome/ER-targeted derivatives. We assumed that 4-PBA targeting to specific organelles, where protein degradation takes place, might reduce the 4-PBA effective concentration.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Organic chemistry synthetic methods and solid-phase peptide synthesis (SPPS) were used for preparing the 4-PBA derivatives. The obtained compounds were evaluated in an ALS Drosophila model that expressed C9orf72 repeat expansion, causing eye degeneration. Targeting to lysosome was validated by the <sup>19</sup>F-nuclear magnetic resonance (NMR) technique.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Several synthesized compounds exhibited a significant biological effect by ameliorating the eye degeneration. They blocked the neurodegeneration of fly retina at different efficacy levels. The most active CS was compound 9, which is a peptide derivative and was targeted to ER. Another active compound targeted to lysosome was compound 4.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Novel CSs were more effective than 4-PBA; therefore, they might be used as a new class of drug candidates to treat ALS and other protein misfolding disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Azoulay-Ginsburg</LastName><ForeName>Salome</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bar-Ilan University, 5290002, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Salvio</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, 00185, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Biology and Pathology, National Research Council, Sapienza University of Rome, 00185, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weitman</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bar-Ilan University, 5290002, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afri</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bar-Ilan University, 5290002, Ramat-Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Physical and Theoretical Chemistry, TU Braunschweig, 38106, Braunschweig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebbinghaus</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Physical and Theoretical Chemistry, TU Braunschweig, 38106, Braunschweig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cestra</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, 00185, Rome, Italy. gianluca.cestra@uniroma1.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Biology and Pathology, National Research Council, Sapienza University of Rome, 00185, Rome, Italy. gianluca.cestra@uniroma1.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruzman</LastName><ForeName>Arie</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8006-4201</Identifier><AffiliationInfo><Affiliation>Bar-Ilan University, 5290002, Ramat-Gan, Israel. gruzmaa@biu.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>3-13325</GrantID><Agency>Ministry of Science and Technology, Israel</Agency><Country/></Grant><Grant><GrantID>3-13325</GrantID><Agency>the Directorate General for Country Promotion (Unit for Scientific and Technological Co-operation)</Agency><Country/></Grant><Grant><GrantID>I-1410-201.9/2017</GrantID><Agency>The Germany Israel Foundation</Agency><Country/></Grant><Grant><GrantID>4</GrantID><Agency>NAAMAT, the Edelson Foundation prize</Agency><Country/></Grant><Grant><GrantID>2</GrantID><Agency>Navon fellowship for PhD students</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmacol Rep</MedlineTA><NlmUniqueID>101234999</NlmUniqueID><ISSNLinking>1734-1140</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010654">Phenylbutyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>7WY7YBI87E</RegistryNumber><NameOfSubstance UI="C075773">4-phenylbutyric acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010654" MajorTopicYN="N">Phenylbutyrates</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Aggregation</Keyword><Keyword MajorTopicYN="N">C9orf72 mutation</Keyword><Keyword MajorTopicYN="N">Chaperones</Keyword><Keyword MajorTopicYN="N">Targeting</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>12</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33661518</ArticleId><ArticleId IdType="doi">10.1007/s43440-021-00226-2</ArticleId><ArticleId IdType="pii">10.1007/s43440-021-00226-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S. Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci. 2019;20:2818&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">6600525</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93:1617&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat J-M, Le MG. Genetics of amyotrophic lateral sclerosis: a review. J Neurol Sci. 2019;399:217&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez CM, Todd PK. New pathologic mechanisms in nucleotide repeat expansion disorders. Neurobiol Dis. 2019;130:104515.</Citation><ArticleIdList><ArticleId IdType="pubmed">31229686</ArticleId><ArticleId IdType="pmc">6689435</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, Al-Chalabi A, Andersen PM, Hosler B, Sapp P, Englund E, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology. 2006;66:839&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421333</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId><ArticleId IdType="pmc">3202986</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">21944779</ArticleId><ArticleId IdType="pmc">3200438</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Nana AL, Yokoyama JS, Seeley WW. C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. Acta Neuropathol. 2019;137:1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">30368547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-J, Jansen-West K, Xu Y-F, Gendron TF, Bieniek KF, Lin W-L, et al. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128:505&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">25173361</ArticleId><ArticleId IdType="pmc">4159567</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Lehmer C, Mart&#xed;nez-S&#xe1;nchez A, Rudack T, Beck F, Hartmann H, et al. In situ structure of neuronal C9orf72 Poly-GA aggregates reveals proteasome recruitment. Cell. 2018;172:696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">29398115</ArticleId><ArticleId IdType="pmc">6035389</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Wang J. C9orf72-dependent lysosomal functions regulate epigenetic control of autophagy and lipid metabolism. Autophagy. 2019;15:913&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">30767689</ArticleId><ArticleId IdType="pmc">6526819</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Q, Yang M, Liang C, Ma L, Zhang W, Jiang Z, et al. c9orf72 and smcr8 mutant mice reveal MTORC1 activation due to impaired lysosomal degradation and exocytosis. Autophagy. 2020;16:1635&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">31847700</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrionero A, Horvitz HR. A C9orf72 ALS/FTD ortholog acts in endolysosomal degradation and lysosomal homeostasis. Curr Biol. 2018;28:1522&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">29731301</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J, Ferguson SM. C9orf72: at the intersection of lysosome cell biology and neurodegenerative disease. Traffic. 2017;18:267&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">28266105</ArticleId><ArticleId IdType="pmc">5389918</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Zhou X, Robins AM, Paushter DH, Kim D, Smolka MB, et al. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol Commun. 2016;4:51.</Citation><ArticleIdList><ArticleId IdType="pubmed">27193190</ArticleId><ArticleId IdType="pmc">4870812</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Liang C, Swaminathan K, Herrlinger S, Lai F, Shiekhattar R, et al. A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. Sci Adv. 2016;2:e1601167.</Citation><ArticleIdList><ArticleId IdType="pubmed">27617292</ArticleId><ArticleId IdType="pmc">5010369</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C, Campanari M-L, Julie Corbier C, Gaucherot A, Kolb-Cheynel I, Oulad-Abdelghani M, et al. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. EMBO J. 2016;35:1276&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">27103069</ArticleId><ArticleId IdType="pmc">4910533</ArticleId></ArticleIdList></Reference><Reference><Citation>Claessen JHL, Kundrat L, Ploegh HL. Protein quality control in the ER: balancing the ubiquitin checkbook. Trends Cell Biol. 2012;22:22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">22055166</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodsky JL. Cleaning up: ER-associated degradation to the rescue. Cell. 2012;151:1163&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23217703</ArticleId><ArticleId IdType="pmc">3521611</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay-Ginsburg S, Trobiani L, Setini A, Favaloro FL, Giorda E, Jacob A, et al. A lipophilic 4-phenylbutyric acid derivative that prevents aggregation and retention of misfolded proteins. Chem A Eur J. 2020;26:1834&#x2013;45.</Citation></Reference><Reference><Citation>Getter T, Zaks I, Barhum Y, Ben-Zur T, B&#xf6;selt S, Gregoire S, et al. A chemical chaperone-based drug candidate is effective in a mouse model of amyotrophic lateral sclerosis (ALS). ChemMedChem. 2015;10:850&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">25772747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez L, Sim V. The therapeutic potential of chemical chaperones in protein folding diseases. Prion. 2014;8:197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">4189890</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch WJ, Brown CR. Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones. 1996;1:109&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9222596</ArticleId><ArticleId IdType="pmc">248462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Y-X, Conn PM. Pharmacoperones as novel therapeutics for diverse protein conformational diseases. Physiol Rev. 2018;98:697&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">29442594</ArticleId><ArticleId IdType="pmc">5966717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb PS, Ayaub EA, Zhou W, Yum V, Dickhout JG, Ask K. The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis. Int J Biochem Cell Biol. 2015;61:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">25660369</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronbeck KR, Rodrigues CMP, Mahmoudi J, Bershad EM, Ling G, Bachour SP, et al. Application of tauroursodeoxycholic acid for treatment of neurological and non-neurological diseases: Is there a potential for treating traumatic brain injury? Neurocrit Care. 2016;25:153&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">26759227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusaczuk M, Bartoszewicz M, Cechowska-Pasko M. Phenylbutyric acid: simple structure&#x2013;multiple effects. Curr Pharm Des. 2015;21:2147&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25557635</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate&#x2013;taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington&#x2019;s disease: a dose-finding study. Mov Disord. 2007;22:1962&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17702032</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia AE, Lalli S, Monsurr&#xf2; MR, Sagnelli A, Taiello AC, Reggiori B, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">25664595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip P, Sharda PR, Cunningham A, Chakrabartty S, Pande V, Chakrabartty A. Quercitrin and quercetin 3-&#x3b2;-D-glucoside as chemical chaperones for the A4V SOD1 ALS-causing mutant. Protein Eng Des Sel. 2017;30:431&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28475686</ArticleId><ArticleId IdType="pmc">5939853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GSA, Antonyuk SV, Hasnain SS. A faulty interaction between SOD1 and hCCS in neurodegenerative disease. Sci Rep. 2016;6:27691.</Citation><ArticleIdList><ArticleId IdType="pubmed">27282955</ArticleId><ArticleId IdType="pmc">4901319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10:99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">18688762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci. 2007;96:729&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17117426</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew CL, Klemm AR, Lloyd JB. Lysosome membrane permeability to amines. Biochim Biophys Acta Biomembr. 1997;1330:71&#x2013;82.</Citation></Reference><Reference><Citation>Bartels AK, G&#xf6;ttert S, Desel C, Sch&#xe4;fer M, Krossa S, Scheidig AJ, et al. KDEL receptor 1 contributes to cell surface association of protein disulfide isomerases. Cell Physiol Biochem. 2019;52:850&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">30958660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma WF, Chen HY, Du J, Tan Y, Cai SH. A novel recombinant protein TAT&#x2013;GFP&#x2013;KDEL with dual-function of penetrating cell membrane and locating at endoplasm reticulum. J Drug Target. 2009;17:329&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">19558358</ArticleId></ArticleIdList></Reference><Reference><Citation>Newstead S, Barr F (2020) Molecular basis for KDEL-mediated retrieval of escaped ER-resident proteins&#x2014;SWEET talking the COPs. J Cell Sci 133:jcs250100</Citation></Reference><Reference><Citation>Murshid A, Presley JF. ER-to-Golgi transport and cytoskeletal interactions in animal cells. Cell Mol Life Sci. 2004;61:133&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745493</ArticleId></ArticleIdList></Reference><Reference><Citation>Koon AC, Chan HYE. Drosophila melanogaster as a model organism to study RNA toxicity of repeat expansion-associated neurodegenerative and neuromuscular diseases. Front Cell Neurosci. 2017;11:70.</Citation><ArticleIdList><ArticleId IdType="pubmed">28377694</ArticleId><ArticleId IdType="pmc">5359753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb HE, Kotlyar V, Nudelman A. NMR chemical shifts of common laboratory solvents as trace impurities. J Org Chem. 1997;62:7512&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11671879</ArticleId></ArticleIdList></Reference><Reference><Citation>Balalaie S, Mahdidoust M, Eshaghi-Najafabadi R. 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate as an efficient coupling reagent for the amidation and phenylhydrazation of carboxylic acids at room temperature. J Iran Chem Soc. 2007;4:364&#x2013;9.</Citation></Reference><Reference><Citation>Mizielinska S, Gr&#xf6;nke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25103406</ArticleId><ArticleId IdType="pmc">4944841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahremany S, Babaev I, Hasin P, Tamir TY, Ben-Zur T, Cohen G, et al. Computer-aided design and synthesis of 1-{4-[(3,4-dihydroxybenzylidene)amino]phenyl}-5-oxopyrrolidine-3-carboxylic acid as an Nrf2 enhancer. ChemPlusChem. 2018;83:320&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">31957349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zer Aviv P, Shubely M, Moskovits Y, Viskind O, Albeck A, Vertommen D, et al. A new oxopiperazin-based peptidomimetic molecule inhibits prostatic acid phosphatase secretion and induces prostate cancer cell apoptosis. Chem Select. 2016;1:4658&#x2013;67.</Citation></Reference><Reference><Citation>Xu W, Xu J. C9orf72 dipeptide repeats cause selective neurodegeneration and cell-autonomous excitotoxicity in Drosophila glutamatergic neurons. J Neurosci. 2018;38:7741&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">30037833</ArticleId><ArticleId IdType="pmc">6705968</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullahi A, Stanojcic M, Parousis A, Patsouris D, Jeschke MG. Modeling acute ER stress in vivo and in vitro. Shock. 2017;47:506&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">27755507</ArticleId><ArticleId IdType="pmc">5348263</ArticleId></ArticleIdList></Reference><Reference><Citation>Guroff G. PC12 cells as a model of neuronal differentiation. In: Cell culture in the neurosciences. New York: Springer; 1985. p. 245&#x2013;72.</Citation></Reference><Reference><Citation>Bartusik D, Tomanek B. Detection of 19F-labeled biopharmaceuticals in cell cultures with magnetic resonance. Adv Drug Deliv Rev. 2013;65:1056&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">23603212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Schiller MR. The carboxy-terminus, a key regulator of protein function. Crit Rev Biochem Mol Biol. 2019;54:85&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">31106589</ArticleId><ArticleId IdType="pmc">6568268</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>